Mes données de santé
The information site for patients treated within the Unicancer network or included in Unicancer network clinical trials. 

About us

Objectives

Principal

 

The aim of our study was to evaluate the incidence of ≥ 4 pathological axillary lymph nodes in ER-positive, HER2-negative early BC patients treated by upfront surgery with SLNB and cALND grade 1-2, with involved SN by micro metastases or macro metastases ineligible for abemaciclib, according to clinicopathological criteria. Predictive factors of ≥ 4 pathological axillary lymph nodes were determined.

 

 

Secondaires 

 

A predictive score of ≥ 4 involved LN macro metastases was created.

Data controller

Institut Paoli Calmettes

232 Boulevard Sainte Marguerite 

13273 Marseille Cedex 09

Categories of data used
Données d’identification (sans donnée nominative)
Origine de données utilisées
Soins
Institut Paoli Calmettes (Marseille)
1990
1991
1992
1993
1994
1995
1996
1997
1998
1999
2000
2001
2002
2003
Population subject to research or data processing

 

D’inclusion :

French cohort: Patients were retrospectively identified from a cohort of 17,097 ER-positive, Her2-negative early BC patients, who underwent upfront surgery in 13 French centers between 1990 and 2023. Patients with SLNB and cALND were selected. We then excluded patients eligible for abemaciclib according to the MonarchE trial criteria of pT3 and/or grade 3 with 1-3 pathological axillary lymph nodes. All patients in 13 French centers between 2001-2023, who underwent upfront surgery with SLNB and cALND, grade 1-2, with involved SN by micro metastases or macro metastases were included.

 

De non inclusion :

 

 

Critère d’évaluation principal :

Predictive factors of ≥ 4 pathological axillary lymph nodes

 

 

Critères d’évaluation secondaires :

the incidence of ≥ 4 pathological axillary lymph nodes in ER-positive, HER2-negative early BC patients treated by upfront surgery with SLNB and cALND grade 1-2, with involved SN by micro metastases or macro metastases ineligible for abemaciclib, according to clinicopathological criteria.

 

 

Legal basis

Traitement de données mené dans l'intérêt public dans le domaine de la santé publique (article 6.1e et 9.2.j du Règlement (UE) n°2016/679)

Internal and external data recipients

institut paoli calmettes

Research start date
24/09/2024
Data retention period

Les données seront conservées pendant la durée légale en vigueur ou tant qu'elles présenteront un intérêt scientifique 

To protect your health data, it is recommended not to disclose personal health information about you or a family member in this form.
We invite you to indicate the facility where you are receiving care and we will ensure that the appropriate connection is established to guarantee the exercise of your request.
CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
Cette question sert à vérifier si vous êtes un visiteur humain ou non afin d'éviter les soumissions de pourriel (spam) automatisées.

The information collected in the questionnaire is not stored on this site but is sent to the data controller mentioned in the research form. This data is collected in order to process your request to exercise your rights.

Data marked with an asterisk in the questionnaire must be provided for the form to be submitted and your request to be processed.

The collected data will be communicated to your data controller and their DPO for processing these requests.

They are kept for the time of analysis and response to the same.You have the right to access, rectify and delete your personal data. You can also object to the processing of your data.

To exercise these rights or for any questions about the processing of your data, you must complete this form.

If you believe, after contacting us, that your "Data Protection" rights are not being respected, you can file a complaint with the relevant data protection authority.